Setting up a UK aesthetic prescribing service in 2026 — typically for botulinum toxin and other POMs used in aesthetic practice — sits at the intersection of medical prescribing and aesthetic practice. The regulatory expectations are tight, the prescriber model has been actively reviewed by MHRA and GPhC, and the dispensing operation must handle prescription-only medicines under proper clinical accountability. This piece is the operational brief for aesthetic clinic owners and the practitioners they work with.
Why aesthetic prescribing is its own category
Aesthetic prescribing in the UK covers POMs used for cosmetic indications — botulinum toxin, certain dermal fillers (where POMs apply), and supporting medications. It sits in distinct regulatory territory because aesthetic practice is often delivered by non-prescribers (nurses, dental professionals, beauty practitioners), with prescribing handled by a separate clinician. This split has been the focus of regulatory and parliamentary attention across 2024-2026.
The prescriber model — face-to-face requirement and remote constraint
MHRA and GPhC have made clear that remote prescribing of botulinum toxin without proper face-to-face consultation is not acceptable. The standard model: the prescriber sees the patient in person before prescribing. Remote-only prescribing for aesthetics has been targeted in enforcement. The operational implication: the prescriber must be physically present or coordinate face-to-face consultations into the patient pathway.
The injector model — who can administer what
Botulinum toxin must be prescribed by a qualified prescriber (medical doctor, dentist, or independent prescribing pharmacist/nurse). Administration can be done by appropriately trained healthcare professionals. The boundary between prescribing and administering has tightened: the prescriber retains clinical accountability, must have seen the patient, and must be available for adverse-event management.
Patient pathway — consultation, consent, treatment, follow-up
Standard aesthetic patient pathways: in-person consultation including medical history and aesthetic expectations, written informed consent, prescribing decision, administration of treatment, and structured follow-up for adverse reactions or unsatisfactory outcomes. Documentation across each step is foundational — aesthetic complaints frequently turn on documentation gaps rather than clinical ones.
Dispensing — POMs under proper clinical accountability
Aesthetic POMs must be dispensed under proper clinical accountability — GPhC-registered pharmacy, prescriber-named prescription, patient-named supply. Bulk supply without patient-specific prescribing is not acceptable. The dispensing partner must be set up to handle aesthetic-specific medicines with appropriate cold-chain where required (botulinum toxin requires careful handling) and patient-specific traceability.
How PExpo supports aesthetic prescribing services
PExpo's clinic model supports aesthetic clinics with structured dispensing on £0 platform fees and a transparent per-request admin client care fee. The prescriber-injector model, face-to-face consultation requirement, and patient-specific traceability are all supported in the workflow. See our clinic model page for the operational scope or our brand model page if you are launching a broader aesthetic brand.
MHRA and GPhC have made clear that remote prescribing of botulinum toxin without proper face-to-face consultation is not acceptable. The prescriber must see the patient in person before prescribing.
Aesthetic complaints frequently turn on documentation gaps. Build the consultation, consent, and follow-up documentation into the workflow.
Setting up a UK aesthetic prescribing service in 2026 is workable when the prescriber model, consultation requirements, and dispensing accountability are built in correctly. The clinics that respect the face-to-face requirement and the prescriber accountability run sustainably. The ones who try to scale remote-only prescribing for aesthetic POMs find themselves in active regulatory territory. See our clinic model page for the dispensing setup or our brand model page for broader aesthetic brand launches.
Frequently asked questions
Can I prescribe botulinum toxin remotely in the UK?
No — MHRA and GPhC have made clear that remote prescribing of botulinum toxin without face-to-face consultation is not acceptable. The prescriber must see the patient in person before prescribing. This has been an active enforcement area across 2024-2026.
Who can prescribe and who can administer aesthetic POMs in the UK?
Botulinum toxin and other POMs must be prescribed by a qualified prescriber — medical doctor, dentist, or independent prescribing pharmacist/nurse. Administration can be done by appropriately trained healthcare professionals. The prescriber retains clinical accountability and must have seen the patient face-to-face.
What do I need to set up a UK aesthetic prescribing service?
A prescriber able to see patients face-to-face, a structured consultation pathway including informed consent, a GPhC-registered dispensing pharmacy partner with patient-specific traceability, CQC registration in England for the clinical service, and documentation across consultation, treatment, and follow-up. PExpo's clinic model handles the dispensing layer with £0 platform fees.
Does PExpo support aesthetic clinics with dispensing?
Yes — PExpo's clinic model includes dispensing for aesthetic POMs under patient-specific prescribing and proper clinical accountability. £0 platform fees with a transparent per-request admin client care fee. See our clinic model page for the operational scope.
